Brukinsa (zanubrutinib) is a kinase inhibitor approved to treat Waldenström's macroglobulinemia (WM). Here's a breakdown of its side effects:
Common side effects
- Low white blood cell (neutrophil) count
- Low platelet count
- Upper respiratory tract infections
- Bleeding or bruising
- Musculoskeletal pain
- Anemia
- Rash
- Show Full Answer
Brukinsa (zanubrutinib) is a kinase inhibitor approved to treat Waldenström's macroglobulinemia (WM). Here's a breakdown of its side effects:
Common side effects:
- Low white blood cell (neutrophil) count
- Low platelet count
- Upper respiratory tract infections
- Bleeding or bruising
- Musculoskeletal pain
- Anemia
- Rash
- Diarrhea
- Cough
Rare but serious side effects:
- Significant bleeding problems
- Severe infections
- Heart rhythm problems
- Liver damage
- Secondary cancers (such as skin carcinomas)
- Harm to an unborn baby if taken during pregnancy It's really important to report any new or worsening symptoms to your care team as soon as possible, especially signs of bleeding, infection (like fever or chills), or irregular heartbeat. Your doctor can help manage side effects and adjust treatment if needed.
November 4